Investigate the efficacy of human immunoglobulin in the adjuvant treatment of neonatal pneumonia. A total of 116 children with neonatal pneumonia were treated in our hospital from March 2022 to March 2024 were selected and they were randomly divided into control group(n=58,receiving conventional treatment)and observation group(n=58,receiving conventional treatment+human immunoglobulin treatment), compar the treatment efficacy,immune function indicators and inflammatory factor levels before and after intervention, and the occurrence of adverse reactions. The total effective rate in the observation group was higher than that in the control group (P<0.05); compared with the control group, the level of inflammatory factors in the observation group was lower after treatment (P<0.05); after treatment, compared with the control group, the level of immune function indicators in the observation group was higher (P<0.05); There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05 ). Human immunoglobulin adjuvant treatment of neonatal pneumonia can reduce the level of inflammatory factors and improve the immune function in children, the treatment efficacy is significant and safe.

Yao Yuan, Wang Yue. Efficacy of human immunoglobulin in adjuvant treatment of neonatal pneumonia and its effect on inflammatory factors and immune function. Frontiers in Medical Science Research (2025), Vol. 7, Issue 1: 65-69. https://doi.org/10.25236/FMSR.2025.070110.

[1] Bondarev D J, Ryan R M, Mukherjee D. The spectrum of pneumonia among intubated neonates in the neonatal intensive care unit[J]. J Perinatol, 2024, 44(9): 1235-1243.

[2] Nair N S, Lewis L E, Dhyani V S, et al. Factors Associated With Neonatal Pneumonia and its Mortality in India: A Systematic Review and Meta-Analysis[J]. Indian Pediatr, 2021, 58(11): 1059-1061.

[3] Ozdemir F E, Alan S, Aliefendioglu D. The diagnostic value of pulmonary near-infrared spectroscopy in the early distinction of neonatal pneumonia from transient tachypnea of the newborn[J]. Pediatr Pulmonol, 2023, 58(11): 3271-3278. 

[4] Abd Almonaem E R, Rashad M M, Emam H M, et al. Tracheal aspirate presepsin: a promising biomarker in early onset neonatal pneumonia[J]. Scand J Clin Lab Invest, 2021 ,81(5): 406-412.

[5] Sun Q, Gao Y, Qiao L, et al. 25(OH)-Vitamin D alleviates neonatal infectious pneumonia via regulating TGFβ-mediated nuclear translocation mechanism of YAP/TAZ[J]. Bioengineered, 2021, 12(1): 8931-8942.

[6] Lekhraj R, Lalezari S, Aguilan JT, et al. Altered abundances of human immunoglobulin M and immunoglobulin G subclasses in Alzheimer's disease frontal cortex[J]. Sci Rep, 2022, 12(1): 6934.

[7] Shao X M, Ye H M, Qiu X S. Practical Neonatology[M]. 5th Edition. Beijing: People's Medical Publishing House, 2019: 367-368 .

[8] Respiratory Studies Group, Branch of Pediatrics,"Chinese Journal of Practical Pediatrics" Expert Consensus on the Diagnosis and Treatment of Mycoplasma pneumoniae Pneumonia in Children (2015 Edition)[J]. Chinese Journal of Practical Pediatrics Clinical, 2015, 30(17): 1304-1308.

[9] Zhou B, Wen X, Zhou J, et al. Assessing Diagnostic Significance of White Blood Cell Count, Serum C-Reactive Protein, and Procalcitonin in Neonatal Pneumonia: A Comparative Analysis[J]. Altern Ther Health Med, 2024, 30(12): 506-510.

[10] Alanezi G, Almulhem A, Aldriwesh M, et al. A triple antimicrobial regimen for multidrug-resistant Klebsiella pneumonia in a neonatal intensive care unit outbreak: A case series[J]. J Infect Public Health, 2022, 15(1): 138-141.

[11] El S M, Elmahdy H, Nassar M, et al. Role of soluble triggering receptors expressed on myeloid cells-1 and 25-hydroxy vitamin D as early diagnostic markers of neonatal Ventilator-associated pneumonia: A prospective cohort study[J]. Pediatr Pulmonol, 2022, 57(9): 2147-2153.

[12] Kriván G, Borte M, Soler-Palacin P, et al. BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children[J]. J Clin Immunol, 2023, 43(3): 557-567.